---
layout: page
title: Suspected Prostate Cancer (2WW)
date: 2026-02-19
type: topic
status: draft
---

<link rel="stylesheet" href="../assets/site.css" />

<div class="tabs" data-tabs>
  <div class="tabs-nav">
    <button class="tab-btn active" data-tab="evidence">Evidence</button>
    <button class="tab-btn" data-tab="draft">DGRefHelp draft</button>
    <button class="tab-btn" data-tab="refs">References</button>
  </div>

  <div class="tab-content active" id="evidence">
    <h2>Evidence summary (triangulated)</h2>
    <ul>
      <li><strong>Incidence</strong>: Prostate cancer is the most common cancer in men in the UK. Incidence increases with age.</li>
      <li><strong>Screening</strong>: There is no national screening programme. Asymptomatic men aged 50+ can request a PSA test after informed discussion (Prostate Cancer Risk Management Programme).</li>
      <li><strong>Assessment</strong>: Diagnosis relies on <strong>DRE</strong> (Digital Rectal Examination) and <strong>PSA</strong> (Prostate Specific Antigen).
        <ul>
          <li><strong>DRE</strong>: A hard, irregular, or nodular prostate is highly suspicious regardless of PSA.</li>
          <li><strong>PSA</strong>: Non-specific; raised in BPH, prostatitis, UTI, and after ejaculation/exercise. Age-specific thresholds improve sensitivity/specificity.</li>
        </ul>
      </li>
      <li><strong>Referral Criteria (NICE NG12)</strong>: Refer urgently (2WW) if prostate feels malignant on DRE <em>OR</em> PSA is above age-specific reference range.</li>
      <li><strong>Secondary Care</strong>: Most patients now proceed to <strong>mpMRI</strong> before biopsy to reduce unnecessary procedures and improve detection of clinically significant cancer.</li>
    </ul>
  </div>

  <div class="tab-content" id="draft">
    <div class="callout" style="margin-bottom: 1rem;">
      <details>
        <summary><strong>Copy/paste HTML (click to expand)</strong></summary>
        <p>Use these blocks to paste into the CMS/site editor.</p>

        <h4>Background</h4>
        <pre>&lt;h3&gt;Background&lt;/h3&gt;
&lt;ul&gt;
  &lt;li&gt;Prostate cancer diagnosis relies on clinical suspicion (symptoms, DRE) and/or elevated PSA.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;PSA is not specific&lt;/strong&gt; to cancer; causes of elevation include BPH, prostatitis, UTI, and physical stimulation.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;mpMRI&lt;/strong&gt; is now standard first-line investigation in secondary care (requires renal function check).&lt;/li&gt;
&lt;/ul&gt;</pre>

        <h4>Assessment</h4>
        <pre>&lt;h3&gt;Assessment&lt;/h3&gt;
&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;Indications for assessment&lt;/strong&gt; (consider DRE + PSA):
    &lt;ul&gt;
      &lt;li&gt;Lower Urinary Tract Symptoms (LUTS): nocturia, frequency, hesitancy, urgency, retention.&lt;/li&gt;
      &lt;li&gt;Erectile dysfunction.&lt;/li&gt;
      &lt;li&gt;Visible haematuria (see &lt;a href="/topics/visible-haematuria"&gt;Haematuria pathway&lt;/a&gt;).&lt;/li&gt;
      &lt;li&gt;Unexplained symptoms (e.g., back pain, weight loss) raising suspicion of metastases.&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Physical Exam (Mandatory)&lt;/strong&gt;:
    &lt;ul&gt;
      &lt;li&gt;&lt;strong&gt;Digital Rectal Examination (DRE)&lt;/strong&gt;: Check for hardness, irregularity, cragginess, nodules, asymmetry, or loss of median sulcus.&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Investigations&lt;/strong&gt;:
    &lt;ul&gt;
      &lt;li&gt;&lt;strong&gt;PSA Test&lt;/strong&gt;:
        &lt;ul&gt;
          &lt;li&gt;Postpone for &lt;strong&gt;1 month&lt;/strong&gt; after treated UTI.&lt;/li&gt;
          &lt;li&gt;Avoid if &lt;strong&gt;ejaculated&lt;/strong&gt; in previous 48 hours.&lt;/li&gt;
          &lt;li&gt;Avoid if &lt;strong&gt;vigorous exercise&lt;/strong&gt; (e.g. cycling) in previous 48 hours.&lt;/li&gt;
          &lt;li&gt;Wait if DRE was vigorous (though gentle DRE has minimal effect).&lt;/li&gt;
        &lt;/ul&gt;
      &lt;/li&gt;
      &lt;li&gt;&lt;strong&gt;U&amp;Es / eGFR&lt;/strong&gt;: Recent result (within 3 months) usually required for MRI contrast.&lt;/li&gt;
      &lt;li&gt;&lt;strong&gt;Urine dip/MSU&lt;/strong&gt;: To exclude infection.&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
&lt;/ul&gt;</pre>

        <h4>Primary Care Management</h4>
        <pre>&lt;h3&gt;Primary Care Management&lt;/h3&gt;
&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;UTI&lt;/strong&gt;: Treat first. Do not refer on PSA alone during active infection. Repeat PSA &gt;1 month after clearance.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Asymptomatic men (Screening requests)&lt;/strong&gt;:
    &lt;ul&gt;
      &lt;li&gt;Counsel on benefits/risks (Prostate Cancer Risk Management Programme).&lt;/li&gt;
      &lt;li&gt;If PSA raised after counselling, refer via 2WW.&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Incidental slightly raised PSA&lt;/strong&gt;: Consider repeating in 4-6 weeks to rule out transient causes (unless examination is abnormal—then refer immediately).&lt;/li&gt;
&lt;/ul&gt;</pre>

        <h4>Who to refer</h4>
        <pre>&lt;h3&gt;Who to refer&lt;/h3&gt;
&lt;h4&gt;Suspected Prostate Cancer (2WW)&lt;/h4&gt;
&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;Abnormal DRE&lt;/strong&gt;: Prostate feels malignant (hard, irregular, craggy, or asymmetrical).&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Elevated PSA&lt;/strong&gt;: PSA level is above the age-specific reference range (see table).&lt;/li&gt;
&lt;/ul&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th&gt;Age (years)&lt;/th&gt;
      &lt;th&gt;PSA Threshold (ng/mL) (NICE NG12)&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;&lt;td&gt;&lt; 40&lt;/td&gt;&lt;td&gt;Use clinical judgement&lt;/td&gt;&lt;/tr&gt;
    &lt;tr&gt;&lt;td&gt;40 – 49&lt;/td&gt;&lt;td&gt;&gt; 2.5&lt;/td&gt;&lt;/tr&gt;
    &lt;tr&gt;&lt;td&gt;50 – 59&lt;/td&gt;&lt;td&gt;&gt; 3.5&lt;/td&gt;&lt;/tr&gt;
    &lt;tr&gt;&lt;td&gt;60 – 69&lt;/td&gt;&lt;td&gt;&gt; 4.5&lt;/td&gt;&lt;/tr&gt;
    &lt;tr&gt;&lt;td&gt;70 – 79&lt;/td&gt;&lt;td&gt;&gt; 6.5&lt;/td&gt;&lt;/tr&gt;
    &lt;tr&gt;&lt;td&gt;&gt; 79&lt;/td&gt;&lt;td&gt;Use clinical judgement*&lt;/td&gt;&lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;
&lt;p class="small"&gt;*In men aged &gt;80, consider comorbidities. Referral is appropriate if cancer would be significant enough to require treatment or palliation.&lt;/p&gt;</pre>

        <h4>Who not to refer</h4>
        <pre>&lt;h3&gt;Who not to refer&lt;/h3&gt;
&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;Active UTI&lt;/strong&gt;: Treat and re-test PSA after 1 month.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Asymptomatic men &lt;50&lt;/strong&gt;: Unless strong family history or genetic risk (e.g. BRCA2).&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Incidental findings&lt;/strong&gt; where patient would not be fit for/does not want investigation/treatment (frailty, severe comorbidities).&lt;/li&gt;
&lt;/ul&gt;</pre>
      </details>
    </div>

    <div id="draftText" class="section">
      <h3>Background</h3>
      <ul>
        <li>Prostate cancer diagnosis relies on clinical suspicion (symptoms, DRE) and/or elevated PSA.</li>
        <li><strong>PSA is not specific</strong> to cancer; causes of elevation include BPH, prostatitis, UTI, and physical stimulation.</li>
        <li><strong>mpMRI</strong> is now standard first-line investigation in secondary care (requires renal function check).</li>
      </ul>

      <h3>Assessment</h3>
      <ul>
        <li><strong>Indications for assessment</strong> (consider DRE + PSA):
          <ul>
            <li>Lower Urinary Tract Symptoms (LUTS): nocturia, frequency, hesitancy, urgency, retention.</li>
            <li>Erectile dysfunction.</li>
            <li>Visible haematuria (see <a href="/topics/visible-haematuria">Haematuria pathway</a>).</li>
            <li>Unexplained symptoms (e.g., back pain, weight loss) raising suspicion of metastases.</li>
          </ul>
        </li>
        <li><strong>Physical Exam (Mandatory)</strong>:
          <ul>
            <li><strong>Digital Rectal Examination (DRE)</strong>: Check for hardness, irregularity, cragginess, nodules, asymmetry, or loss of median sulcus.</li>
          </ul>
        </li>
        <li><strong>Investigations</strong>:
          <ul>
            <li><strong>PSA Test</strong>:
              <ul>
                <li>Postpone for <strong>1 month</strong> after treated UTI.</li>
                <li>Avoid if <strong>ejaculated</strong> in previous 48 hours.</li>
                <li>Avoid if <strong>vigorous exercise</strong> (e.g. cycling) in previous 48 hours.</li>
                <li>Wait if DRE was vigorous (though gentle DRE has minimal effect).</li>
              </ul>
            </li>
            <li><strong>U&Es / eGFR</strong>: Recent result (within 3 months) usually required for MRI contrast.</li>
            <li><strong>Urine dip/MSU</strong>: To exclude infection.</li>
          </ul>
        </li>
      </ul>

      <h3>Primary Care Management</h3>
      <ul>
        <li><strong>UTI</strong>: Treat first. Do not refer on PSA alone during active infection. Repeat PSA &gt;1 month after clearance.</li>
        <li><strong>Asymptomatic men (Screening requests)</strong>:
          <ul>
            <li>Counsel on benefits/risks (Prostate Cancer Risk Management Programme).</li>
            <li>If PSA raised after counselling, refer via 2WW.</li>
          </ul>
        </li>
        <li><strong>Incidental slightly raised PSA</strong>: Consider repeating in 4-6 weeks to rule out transient causes (unless examination is abnormal—then refer immediately).</li>
      </ul>

      <h3>Who to refer</h3>
      <h4>Suspected Prostate Cancer (2WW)</h4>
      <ul>
        <li><strong>Abnormal DRE</strong>: Prostate feels malignant (hard, irregular, craggy, or asymmetrical).</li>
        <li><strong>Elevated PSA</strong>: PSA level is above the age-specific reference range (see table).</li>
      </ul>

      <table>
        <thead>
          <tr>
            <th>Age (years)</th>
            <th>PSA Threshold (ng/mL) (NICE NG12)</th>
          </tr>
        </thead>
        <tbody>
          <tr><td>< 40</td><td>Use clinical judgement</td></tr>
          <tr><td>40 – 49</td><td>> 2.5</td></tr>
          <tr><td>50 – 59</td><td>> 3.5</td></tr>
          <tr><td>60 – 69</td><td>> 4.5</td></tr>
          <tr><td>70 – 79</td><td>> 6.5</td></tr>
          <tr><td>> 79</td><td>Use clinical judgement*</td></tr>
        </tbody>
      </table>
      <p class="small">*In men aged >80, consider comorbidities. Referral is appropriate if cancer would be significant enough to require treatment or palliation.</p>

      <h3>Who not to refer</h3>
      <ul>
        <li><strong>Active UTI</strong>: Treat and re-test PSA after 1 month.</li>
        <li><strong>Asymptomatic men &lt;50</strong>: Unless strong family history or genetic risk (e.g. BRCA2).</li>
        <li><strong>Incidental findings</strong> where patient would not be fit for/does not want investigation/treatment (frailty, severe comorbidities).</li>
      </ul>

      <h3>Local agreement needed</h3>
      <ul>
        <li>[ ] <strong>PSA Thresholds</strong>: Confirm if local lab uses NICE NG12 thresholds or different age-specific values.</li>
        <li>[ ] <strong>eGFR requirement</strong>: Confirm if recent renal function is mandatory on referral form for MRI triage.</li>
        <li>[ ] <strong>MRI Safety</strong>: Checklist often required (pacemaker, metal fragments) at referral.</li>
      </ul>
    </div>
  </div>

  <div class="tab-content" id="refs">
    <h3>References</h3>
    <ol>
      <li><strong>NICE NG12</strong>. <em>Suspected cancer: recognition and referral</em>. 2015 (updated 2023). <a href="https://www.nice.org.uk/guidance/ng12">https://www.nice.org.uk/guidance/ng12</a></li>
      <li><strong>Prostate Cancer UK</strong>. <em>Consensus on PSA thresholds</em>. <a href="https://prostatecanceruk.org/for-health-professionals/guidelines/navigating-nice-ng12-and-pcrmp-guidelines-on-psa-testing">https://prostatecanceruk.org/</a></li>
      <li><strong>NICE CKS</strong>. <em>Prostate cancer</em>. <a href="https://cks.nice.org.uk/topics/prostate-cancer/">https://cks.nice.org.uk/topics/prostate-cancer/</a></li>
    </ol>
  </div>
</div>

<script src="../assets/site.js"></script>
